Department of Epidemiology and Biostatistics, School of Public Health, Anhui Medical University, Hefei, Anhui 230032, China.
Department of Head and Neck, Breast Surgery, Anhui Provincial Cancer Hospital (West Branch of The First Affiliated Hospital of University of Science and Technology of China), Hefei, Anhui 230088, China.
Clin Chim Acta. 2018 Sep;484:284-292. doi: 10.1016/j.cca.2018.06.012. Epub 2018 Jun 9.
A meta-analysis was performed to observe whether a difference in miRNA-221/222 expression exists in thyroid cancer with normal thyroid or BTLs (benign thyroid lesions) and, under this premise, assess its diagnostic efficacy for thyroid cancer.
Systematic electronic literature searches were conducted to include PubMed, the Cochrane Central Register of Controlled Trials, and Web of Science. The combined fold change (FC) was calculated, and pooled estimates of sensitivity, specificity, diagnostic odds ratio (DOR) and summary receiver operating characteristic (SROC) curves were calculated.
Twenty-seven articles were included in this meta-analysis. The combined FC of miRNA-221/222 were 13.85 and 13.75 in thyroid cancer with normal control. For miRNA-221/222, the pooled sensitivity was 0.79 (95% CI = 0.73-0.85), specificity was 0.84 (95% CI = 0.76-0.90) and AUC (area under the curve) value was 0.88 (0.85-0.91). For miRNA-221, the pooled sensitivity was 0.82 (95% CI = 0.76-0.86) and specificity was 0.84 (95%CI = 0.74-0.91). For miRNA-222, the pooled sensitivity was 0.78 (95%CI = 0.68-0.85) and specificity was 0.83 (95% CI = 0.70-0.92).
Differences in expression levels of miRNA-221/222 can provide clues for exploring the etiology of thyroid cancer. In addition, miRNA-221/222 were promising molecular biomarkers that may significantly improve the diagnostic accuracy of thyroid cancer.
进行荟萃分析以观察 miRNA-221/222 的表达差异是否存在于甲状腺癌与正常甲状腺或 BTL（良性甲状腺病变）中，并在此前提下评估其对甲状腺癌的诊断效能。
系统地进行电子文献检索，包括 PubMed、Cochrane 对照试验中心注册库和 Web of Science。计算合并的折叠变化（FC），并计算敏感性、特异性、诊断比值比（DOR）和汇总受试者工作特征（SROC）曲线的汇总估计值。
本荟萃分析纳入了 27 篇文章。miRNA-221/222 在甲状腺癌与正常对照组中的合并 FC 分别为 13.85 和 13.75。对于 miRNA-221/222，汇总敏感性为 0.79（95%CI=0.73-0.85），特异性为 0.84（95%CI=0.76-0.90），AUC 值为 0.88（0.85-0.91）。对于 miRNA-221，汇总敏感性为 0.82（95%CI=0.76-0.86），特异性为 0.84（95%CI=0.74-0.91）。对于 miRNA-222，汇总敏感性为 0.78（95%CI=0.68-0.85），特异性为 0.83（95%CI=0.70-0.92）。
miRNA-221/222 表达水平的差异可为探索甲状腺癌的病因提供线索。此外，miRNA-221/222 是很有前途的分子生物标志物，可能显著提高甲状腺癌的诊断准确性。
